Diaceutics | 1H24 Results – Return to Profitability in Sight
Diaceutics has reported results for 1H24 in accordance with the trading statement from July which translated into a net loss for the half of £2.6m with negative EBITDA of £1.3m. The reduced financials reflect the continuing high pace of development and data acquisition for the DXRX platform together with an increased focus on marketing, which raised costs; head count ended the period at 206, 28% higher YoY. However, the company reiterated its guidance that the two-year phase of accelerated investment is nearing completion and its expectation that the company will return to profitability and net free cash flow generation from 2025.
Capital Access Group advises companies on effective engagement with investors. Our experienced team offers market-leading access with hard-to-reach investors, including smaller institutions, pension funds and private client fund managers. These under-serviced investors are located not only in London but across the regions of the UK and Europe. We have an unrivalled knowledge of this extensive audience, to whom our published research is distributed, as well as to larger institutions. We offer this service as part of an integrated investor communications strategy to promote a company’s investment story.
Our clients, ranging from AIM to FTSE 100 companies, benefit from our professional, long-term relationships with investors. Not only do we identify and target investors, we contact them directly and relay their views back to clients with analysis, interpretation and advice. This ensures that our clients are in control of their investor engagement. The objective is to improve the reach and engagement with investors, which in turn strengthens the share price.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.